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Objective: Currently, intravesical bacille Calmette-Guérin (BCG) instillation is the 
standard treatment for patients with an intermediate to high risk of bladder cancer. 
Nevertheless, BCG-refractory generation is a common process during treatment. 
We hypothesized that sunitinib, a vascular endothelial growth factor (VEGF) recep-
tor inhibitor, can synergistically enhance the immunotherapeutic effect of BCG on 
bladder tumor growth.
Materials and Methods: The 50% inhibitory concentration (IC50) of BCG and su-
nitinib in various transitional cell carcinoma (TCC) cell lines was determined by the 
MTT method. The therapeutic effects of BCG, sunitinib, and their combination on 
MBT-2 tumors were investigated in both orthotopic bladder cancer and subcutane-
ously inoculated tumor models in mice. Evaluated parameters included the tumor 
growth rate and tumor burden in the bladder, tumor volume in the subcutaneous 
site, survival rate, serum cytokine changes, and mean vascular density in tumor tissues.
Results: BCG and sunitinib showed in vitro cytotoxicity to tested TCC cell lines 
with slight variations in IC50. Sunitinib had an in vitro synergistic effect on BCG 
cytotoxicity in TCC cells. BCG and sunitinib had individual tumor suppression 
activities in mice MBT-2 tumors in both the orthotopic and subcutaneous models. 
Surprisingly, synchronous combination treatment using BCG and sunitinib did not 
demonstrate synergistic suppression efficacy in animal tumor models. Inhibition of 
tumor growth, increased survival rate, and decreased mean vascular density were 
observed in mice treated with BCG, sunitinib, and synchronous cotreatment. In 
contrast, no therapeutic efficacy was seen in mice treated with BCG and sunitinib 
metachronously.
Conclusions: BCG and the VEGF receptor inhibitor sunitinib had significant suppres-
sive effects in mice bladder cancer models when administered individually. The un-
derlying mechanisms by which they counteract cytotoxicity and the interaction of 
BCG and sunitinib during cotreatment require further investigation.
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1.  Introduction
Transitional cell carcinoma (TCC) of the bladder is the 
fifth most common cancer in the US with an estimated 
68,810 new cases and 14,100 deaths in 2008.1,2 
Annually, approximately 336,000 people are diagnosed 
with bladder cancer worldwide. In Taiwan, 681 victims 
died of bladder cancer in 2006 according to the registra-
tion statistics of the Department of Health, Executive 
Yuan. TCC is histopathologically classified into three 
types: superficial (papillary tumors), confined to the 
bladder wall (pT1 and pTa tumors), and invasive (stages 
T2–T4).3 Approximately 30% of patients with papillary 
tumors will progress to invasive TCC, for which a radical 
cystectomy is standard therapy. Unfortunately, bladder 
cancer has the highest rate of recurrence, at 50–80%, of 
any cancer. Half of patients with muscle-invasive blad-
der cancer will develop metastatic disease.4 The treat-
ment goal for superficial bladder cancer is to reduce 
tumor recurrence and prevent tumor progression, which 
would require additional aggressive therapies.
Bladder cancer is the most expensive of all cancers 
to treat because of the high recurrence rate. For bladder 
cancer, intravesical chemo/immunotherapy is widely 
used as adjuvant therapies after surgical transurethral 
resection of the superficial bladder, while systemic ther-
apy is typically reserved for higher-stage, muscle-invading, 
or metastatic disease. The goal of intravesical therapy is to 
eradicate existing or residual tumors through direct cy-
toablation or immunostimulation. A good response can 
usually be obtained with mitomycin C or bacille Calmette-
Guérin (BCG) instillation. Nevertheless, disease relapse 
and progression are frequently observed in approxi-
mately 15% of clinical patients.5 This fact has prompted 
strong demands to develop more effective therapies for 
superficial bladder cancer after transurethral resection. 
Therefore, new targets need to be identified to treat a 
greater range of patients. Targeted therapy with novel 
agents directed at specific molecular pathways is a 
promising avenue to achieve such progress.
Angiogenesis plays an essential role in tumor growth, 
invasion, and metastasis. Vascular endothelial growth 
factor (VEGF) and its receptors are considered to be im-
portant regulators of angiogenesis. They are mediated 
through the VEGF-specific tyrosine-kinase receptors 
(TKRs), and blocking this pathway is a promising thera-
peutic strategy for inhibiting angiogenesis and tumor 
growth. Various clinical trials have validated the clinical 
importance of anti-VEGF and anti-VEGF receptor (VEGFR) 
therapy. Currently, the humanized monoclonal antibody, 
bevacizumab (which blocks VEGF-A), and the tyrosine 
kinase inhibitors (TKIs), sunitinib and sorafenib (which 
inhibit VEGFRs), are approved for patients with various 
malignancies, and several others are expected in coming 
years. Sunitinib and sorafenib were recently demon-
strated to improve progression-free survival in patients 
with metastatic renal cell carcinoma.6–9 Therefore, we 
speculate that these agents should also be beneficial for 
bladder carcinoma.
The specific hypothesis of this study is that sunitinib 
can synergistically enhance the immunotherapeutic effect 
of BCG on bladder tumor growth both in vitro and in vivo.
2.  Materials and Methods
2.1.  TCC cell lines and agents
The human TCC cell lines, TCC8701, TCC8702, TCC9202, 
and TCC8301, were established in our laboratory from 
clinical specimens of patients with bladder cancer. T24 
and the mouse TCC cell line, MBT2 (purchased from 
American Type Culture Collection [ATCC], Manassas, VA, 
USA), were used in this study. They were maintained 
in RPMI-1640 medium supplemented with 10% heat-
inactivated fetal calf serum (Gibco, Grand Island, NY, 
USA), 100 units/mL penicillin, and 100 mg/L streptomycin 
(both from Sigma, St. Louis, MO, USA) at 37°C, in an air 
atmosphere with 5% CO2. The Connaught substrain of 
Mycobacterium bovis BCG (ImmuCyst, Sinofi Pasteur 
Limited, Toronto, Ontario, Canada) was used in this 
study. It is a freeze-dried preparation of an attenuated 
strain of M bovis containing viable bacteria of the 
Connaught strain of BCG, which is formulated to contain 
81 mg (dry weight) of BCG and 5% w/v monosodium 
glutamate. This amount of BCG provides at least 180 
million colony-forming units. It promotes a local inflam-
matory reaction with histiocytic and leucocytic infiltration 
of the urinary bladder. The local inflammatory effects are 
associated with an apparent elimination or reduction of 
superficial cancerous lesions of the urinary bladder. 
Sunitinib malate (Sutent®, SU11248, NY, USA) is an orally 
bioavailable small-molecule inhibitor of multiple recep-
tor tyrosine kinase domains, including VEGFR-1 and -2, 
platelet-derived receptor -α and -β, and the KIT receptor. 
It inhibits multiple signaling pathways, resulting in a dual 
action of antiproliferation and antiangiogenesis. Sunitinib 
used in this study was kindly provided by Pfizer (Taipei, 
Taiwan) with no mutual financial conflict or interest.
2.2.  Mice and animal care
Pathogen-free 6–8-week-old female C3H/HeN mice 
(Animal Center, National Defense Medical Center, Taipei, 
Taiwan) were used for these experiments. Animal care 
and experimental procedures were in accordance with 
institutional guidelines.
2.3.  In vitro combined treatment of bladder 
cancer cells with BCG and sunitinib
Cells were exposed to BCG, sunitinib, or their combina-
tion for 72 hours. Cellular chemosensitivity was assayed 
using a modified 3-(4,5-dimethylthiazo-2-yl)-2,5-diphenyl 
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tetrazolium (MTT; Sigma) assay to determine cell viability 
in vitro.10 In brief, MBT-2 cells (5,000 cells/well) in 100 μL 
of culture medium were seeded into 96-well micro-
plates and incubated at 37°C for 24 hours before drug 
exposure. Plated cell numbers were calculated to keep 
control cells growing in the exponential phase through-
out the incubation period. For concurrent treatment, cells 
were treated with agents (each in 100 μL of culture me-
dium) and incubated for 72 hours. At that point, 50 μL of 
MTT (2 mg/mL in RPMI medium) was added to each well 
and allowed to react for 2.5 hours. The blue formazan 
crystals formed were pelleted to the well bottoms by 
centrifugation (3,000 rpm/5 minutes), separated from 
the supernatant, and dissolved in 150 μL of DMSO. The 
optical density was determined by absorbance spectrom-
etry at 492 nm using a microplate reader (MRX-2; Dynex 
Technologies, Chantilly, VA, USA). Three separate experi-
ments with triplicate runs for each run were performed 
to obtain the mean cell viability. Drug concentrations in-
hibiting cell growth by 50% (IC50) were determined using 
a dose-effect analysis model as previously described.11
2.4.  Median effect analysis of combined 
cytotoxic effects
The combined effects of BCG and an anti-VEGF agent 
were subjected to a median effect analysis with a mutu-
ally nonexclusive model as previously described.12 
Control experiments replaced the active agent, i.e., ei-
ther BCG or sunitinib, with drug-free medium. For exam-
ple, control experiments for the combined protocol of 
“BCG + sunitinib” were “sunitinib + drug-free medium” 
and “BCG + drug-free medium.” By combining two agents 
at graded concentrations, numerous combined effects 
of growth inhibition were obtained and analyzed using 
the computer software Calcusyn1 (Version 1.1.1, 1996; 
Biosoft, Cambridge, UK). For each combined effect of 
growth inhibition or the fraction affected (Fa), a combi-
nation index (CI) was generated. The effects of the com-
bination were then transformed and displayed as Fa-CI 
plots. CI < 1, = 1, and > 1 indicate synergism, additivism, 
and antagonism, respectively. Various degrees of syner-
gism or antagonism can occur in distinct Fa ranges. We 
also used the statistical function f(u)1,2 = f(u)1 + f(u)2, 
where f(u)1 is the fraction unaffected by drug 1, f(u)2 is 
the fraction unaffected by drug 2, and f(u)1,2 is the frac-
tion unaffected by either drug 1 or 2. The expected (pre-
sumed to be additive) and observed survival rates of TCC 
cells were thus obtained from the three independent 
drug-combination treatments. Results were analyzed by 
Student’s t-test, and a statistically significant difference 
was accepted when p < 0.05.
2.5.  MBT-2 orthotopic tumor implantation
MBT-2 tumor cells were subjected to passage in vitro. 
Single-cell suspensions were prepared from tissue culture 
flasks by trypsinization and adjusted to the required 
concentration of 5 × 106 cells/mL. Mice were anesthe-
tized in groups of five with a single dose of an intraperito-
neal injection of ketamine HCl/xylocaine (100 mg/15 mg 
body weight per mouse) before the study. The bladder 
was catheterized via the urethra with a 24-gauge plastic 
intravenous cannula under sterile conditions. The blad-
der was then traumatized by instilling 0.1 mL of a 0.1 N 
HCl solution for 15 seconds, it was neutralized with 
0.1 mL 0.1 N KOH and then flushed with sterile saline. 
The tumor cell suspension (5 × 105 cells in 0.1 mL 50% 
normal mouse serum) was instilled via the cannula. The 
urethra was compressed with a serrefine clamp for 30 
minutes to prevent premature bladder evacuation. 
Under these conditions, macroscopic tumors usually de-
veloped in mice which resulted in death within 6 weeks 
without treatment.
2.6.  Immunotherapy of orthotopic bladder 
tumors using BCG, sunitinib, or their 
combination
For intravesical therapy, mice were anesthetized, cathe-
terized, and administered BCG (0.18 mg/mL), sunitinib 
(0.25 mg/mL), or their combination in 0.1 mL PBS and re-
tained for 1 hour. Treatment began 3 days after MBT-2 
tumor implantation, and it was given twice weekly for a 
total of six doses. In addition, negative control mice 
were only injected with 0.1 mL PBS. The activity, body 
weight, and survival of mice were monitored daily. After 
a mouse died, it was frozen and kept for further his-
topathological evaluation until the end of the study. 
Cumulative survival rates of treated MBT-2-bearing mice 
were periodically determined during 42 days of observa-
tion. A total of 10 to 12 mice were used per experiment 
group, and each study was repeated twice.
2.7.  Treatment of subcutaneously inoculated 
bladder tumors in mice
The therapeutic effects of BCG, sunitinib, and their com-
bination were also evaluated in a subcutaneous tumor 
model. The subcutaneous tumor model was performed 
by subcutaneous needle inoculation of 107 MBT-2 tumor 
cells in 0.5 mL of a PBS solution. Tumor nodules were 
visible at approximately 10 days, and treatment began 
twice weekly with an intraperitoneal injection of BCG 
(0.18 mg/mL), sunitinib (0.25 mg/mL), or their combina-
tion in 0.1 mL PBS for six injections in total. The activity, 
body weight, and survival of mice were monitored daily. 
The volume of tumor growth was monitored weekly. 
The tumor volume was calculated using the following 
formula: volume = 0.52 × L × W × H, where L is the length or 
largest diameter, W is the width or smallest diameter, 
and H is the height (all in mm).13 After 42 days, mice were 
sacrificed, tumors were sent for histopathological exami-
nation, and sera were collected for cytokine detection.
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2.8.  Histological examination
Bladder sections (4 μm) were assessed by hematoxylin 
and eosin staining for intravesical tumors. Briefly, mice 
were sacrificed, and the bladders were perfused and 
fixed with 10% neutral buffered formalin. Standardized 
cross-sections were obtained from the bladder tissue 
border, stained in hematoxylin and eosin, and evaluated 
on a Presage image analysis system (Advanced Imaging 
Concepts, Princeton, NJ, USA). The tumor incidence, 
tumor loci, and histological characteristics of bladder 
sections were examined.
2.9.  Quantification of MVD
Mean vascular density (MVD) in the tumor was counted 
after immunostaining with an anti-CD34 monoclonal 
antibody. Five microscopic fields at 400× magnification 
from selected specimens were examined for the pres-
ence of microvessels, and MVD was determined as the 
average number of microvessels per 400× field.
2.10.  Serum cytokine determination
Blood samples of mice were centrifuged. Serum was re-
covered at the study completion and examined for the 
concentration of various individual cytokines. Interleukin 
(IL)-1, IL-2, VEGF, regulated on activation normal T cell 
expressed and secreted (RANTES), and monocyte chemo-
attractant protein (MCP)-1 levels were measured with 
a quantitative enzyme-linked immunosorbent assay kit 
(R and D Bioscience, San Diego, CA, USA) according to 
the manufacturer’s directions. Each experiment was 
performed in duplicate.
2.11.  Statistical analysis
Tumor growth inhibition was analyzed with the general-
ized estimating equation test from the calculated 
mean ± standard deviation of tumor weights. The Mann-
Whitney U-test was used for statistical comparison of 
cytokine changes, with differences considered signifi-
cant at p < 0.05. For cumulative survival rates, Kaplan-
Meier estimates were calculated for multiple-comparison 
methods, with differences considered statistically signif-
icant at p < 0.05.
3.  Results
3.1.  In vitro cytotoxic effects of BCG, sunitinib, 
and their combination
The toxic effects of BCG and sunitinib individually were 
significant after culture for 72 hours (Table 1). A lower 
concentration of BCG (0.18 mg/mL) had higher cytotox-
icity than a higher concentration of BCG (0.36 mg/mL) 
(data not shown). Among various cell lines, IC50 values 
of sunitinib were 0.70 in TCC8701, 0.92 in TCC8702, and 
0.97–1.85 μM in the TCC9202 and TCC8301 cell lines. 
The IC50 value for BCG was 0.054 μg/mL in T24 TCC cells 
(Table 1). The combination of BCG and sunitinib also had 
a cytotoxic effect on TCC cells. Median effect analysis for 
the in vitro combined treatment revealed that sunitinib 
had a strong synergistic effect on BCG cytotoxicity to-
ward T24 and MBT-2 TCC cells with CIs of 0.28 and 0.22, 
respectively (Figure 1). The combined effects were analyzed 
at low cytotoxic concentrations of BCG (0.05 mg/mL) 
with sunitinib (0.1, 1, and 10 μM).
3.2.  Tumor incidence in the orthotopic bladder 
cancer model
The tumor incidence were 86%, 61%, 35%, 67%, and 80% 
in the control, BCG, sunitinib, synchronous cotreatment, 
and metachronous cotreatment groups, respectively. There 
were markedly decreased tumor growth incidences in mice 
treated with sunitinib, BCG, and synchronous cotreatment 
compared with those in controls and mice subjected to 
metachronous cotreatment (p < 0.01, Figure 2).
3.3.  Tumor burden comparison
In the orthotopic bladder cancer model, bladder wet 
weights at week 6 were 1,800 ± 955, 970 ± 537, 680 ± 
407, 820 ± 686, and 1,580 ± 1,247 mg in the control, BCG, 
sunitinib, and synchronous and metachronous cotreat-
ment groups, respectively (Figure 3A). The bladder wet 
weight was indirectly used to represent the tumor bur-
den in mice. The bladder size and wet weight were much 
lower in mice treated with BCG, sunitinib, and synchronous 
cotreatment (p < 0.01).
In the subcutaneous tumor model, the MBT-2 tumor 
volume at week 6 was 2.39 ± 1.92, 1.52 ± 1.14, 1.35 ± 
0.95, 1.68 ± 1.24, and 2.45 ± 1.75 cm3 in the control, BCG, 
sunitinib, and synchronous and metachronous cotreat-
ment groups, respectively (Figure 3B). Tumor sizes were 
much smaller in mice treated with BCG, sunitinib, and 
synchronous cotreatment (p < 0.01).
Table 1  IC50 values of BCG (bacille Calmette-Guérin) and 
sunitinib in various transitional cell carcinoma 
cell lines
Cell line
 IC50
 BCG (mg/mL) Sunitinib (μM)
TCC8301 0.028 1.85
TCC8701  0.032 0.70
TCC8702 0.023 0.92
TCC9202 0.025 0.97
T24 0.054 1.17
MBT-2 0.680 16.33
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Figure 2 Tumor incidence in an orthotopic bladder cancer model 
(n = 24 in each subgroup). BCG = bacille Calmette-Guérin.
3.4.  Survival rate
Survival rates of mice with orthotopic bladder tumors at 
week 6 were 30%, 63%, 78%, 55%, and 33% in the con-
trol, BCG, sunitinib, and synchronous and metachronous 
cotreatment groups, respectively (Figure 4A). Mice 
treated with sunitinib and BCG had much higher survival 
rates than those in the control group and mice treated 
with metachronous cotreatment (p < 0.001).
In the subcutaneous tumor model, survival rates at 
week 6 were 33%, 88%, 75%, 67%, and 20% in the con-
trol, BCG, sunitinib, and synchronous and metachronous 
cotreatment groups, respectively (Figure 4B). Mice treated 
with BCG, sunitinib, and synchronous cotreatment had 
much higher survival rates than those in the control 
group and mice treated with metachronous cotreatment 
(p < 0.001).
3000
2500
2000
1500
1000
500
0
Co
nt
ro
l
BC
G
Su
ni
nib
Sy
nc
hr
on
ou
s
co
tre
atm
en
t
M
et
ac
hr
on
ou
s
co
tre
atm
en
t
*
*
*
*p < 0.01
Bl
ad
de
r 
w
et
 w
ei
gh
t (
m
g)
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Co
nt
ro
l
BC
G
Su
ni
nib
Sy
nc
hr
on
ou
s
co
tre
atm
en
t
M
et
ac
hr
on
ou
s
co
tre
atm
en
t
*
*
*
*p < 0.01
Su
bc
ut
an
eo
us
 tu
m
or
 v
ol
um
e 
(c
m
3 )
A B
Figure 3 Changes in (A) the orthotopic bladder wet weight and (B) volume of subcutaneous MBT-2 tumors in C3H mice at 6-week 
intervals (n = 24 in each group). BCG = bacille Calmette-Guérin.
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Figure 1 Analysis of the median effect in in vitro combined treatment of BCG (bacille Calmette-Guérin) and sunitinib in (A) T24 
and (B) MBT2 transitional cell carcinoma cells. CI = combination index; Fa = growth inhibition or fraction affected.
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3.5.  Changes in mouse body weight during 
therapy
There was no significant difference in body weights be-
fore and after the experiment in any study group (data 
not shown). The average body weight was decreased in 
all mice compared with that in control mice, which may 
have been due to stress or the treatment process.
3.6.  Cytokine levels after intravesical 
instillation
Markedly increased serum IL-1 and IL-6 levels were ob-
served in mice subjected to BCG and sunitinib cotreat-
ment, either synchronously or metachronously (Table 2). 
In contrast, all measured cytokines, including IL-1, IL-2, 
VEGF, RANTES, and MCP-1, were markedly suppressed 
in mice treated with BCG or sunitinib alone. Interestingly, 
VEGF levels were also decreased in mice treated with BCG 
compared with those in the control group (316.2 ng/mL 
vs. 592.0 ng/mL, p < 0.001) and sunitinib-treated mice 
(422.5 ng/mL vs. 592.0 ng/mL, p < 0.01).
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Figure 4 Survival rate changes in (A) orthotopic bladder and (B) subcutaneous MBT-2 tumors in C3H mice. BCG = bacille 
Calmette-Guérin.
3.7.  Changes in MVD in tumor tissues
Tumors in the BCG and sunitinib groups had markedly 
decreased MVDs compared with those in the control 
and cotreatment groups, in both the orthotopic bladder 
and subcutaneous tumor models (p < 0.01) (Table 3, 
Figure 5).
4.  Discussion
Intravesical immuno- and chemotherapy, surgery, and 
systemic chemotherapy are all critical elements in man-
aging patients with bladder cancer. Despite advances in 
these modalities, newer treatment paradigms are sought 
to improve patient outcomes. Targeted therapy with novel 
agents directed at specific molecular pathways is a theo-
retically promising avenue to achieve such progress.
Experimental and clinical data, including approval of 
the multi-targeted drugs sunitinib and sorafenib, indi-
cate that exciting results, including tumor regression, 
can be expected from the combined targeting of different 
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pathways in the tumor angiogenesis scenario, especially 
with certain types of cancer. Sunitinib malate and soraf-
enib are novel US Food and Drug Administration (FDA)-
approved antiangiogenic agents which were recently 
demonstrated to improve progression-free survival in 
patients with metastatic renal cell carcinoma.14–16 
However, the two small-molecule TKIs currently FDA-
approved for metastatic renal cell carcinoma (sunitinib 
and sorafenib) are not TKR-specific. Despite the many 
trials reporting clinical efficacies of this new class of 
therapeutics, the exact molecular mechanism account-
ing for their clinical effects is still largely unknown. While 
the clinical efficacy of molecular-targeted therapy in pa-
tients with metastatic renal cell carcinoma (mRCC) was 
found to be impressive in some patients, approximately 
60% of patients with mRCC do not respond to these 
TKIs. It is now clear that there are inherent limitations 
and disadvantages when using these therapeutics as 
monotherapy agents. It has been hypothesized that 
monotherapy with any single TKI can potentially be lim-
ited by tumor cell adaptation and compensation, with 
overexpression of non-targeted oncogenic growth factor 
or TKRs that confer resistance to tumor cells. This hy-
pothesis is supported by the observation that in those 
patients who show a response, the duration of clinical re-
sponse is typically approximately 10–12 months,17 during 
which clonal expansion of resistant tumor cells may occur.
The main mechanisms of these new drugs are defined 
as preventing tumor growth by inhibiting angiogenesis 
Table 2  Serum cytokine changes in mice 6 weeks after BCG (bacille Calmette-Guérin), sunitinib, or their combined treatment 
in a subcutaneous tumor model*
Study group
 Cytokines (μg/mL)
 IL-1 IL-6 VEGF RANTES MCP-1
Control (n = 8) 22.0 ± 1.1  570.6 ± 10.8 592.0 ± 14.6 139.3 ± 27.8 94.0 ± 9.9
BCG (n = 20) 0  34.7 ± 3.2 316.2 ± 20.3 0 0
Sunitinib (n = 17) 0  51.1 ± 3.7 422.5 ± 44.7  7.7 ± 4.5 0
Synchronous cotreatment (n = 12) 447.6 ± 71.7  617.5 ± 19.1 398.7 ± 31.6 10.5 ± 8.4 48.4 ± 0.4
Metachronous cotreatment (n = 5) 373.7 ± 84.9 1129.9 ± 27.2 391.1 ± 53.4  91.6 ± 37.4 50.4 ± 5.4
*Data presented as mean ± standard deviation. IL = interleukin; VEGF = vascular endothelial growth factor; RANTES = regulated on activation 
normal T cell expressed and secreted; MCP = monocyte chemoattractant protein.
Figure 5 Representative vascular density of orthotopic bladder 
tumors under 400× magnifications (Hematoxylin & eosin stain).
Table 3  Mean vascular density in tumor tissues of orthotopic bladder and subcutaneous MBT-2 tumors in C3H mice
 Mean vascular density (×400)
Model 
Control BCG Sunitinib 
Synchronous Metachronous
    cotreatment cotreatment
Orthotopic bladder 3.3 ± 0.8 1.3 ± 0.3† 1.7 ± 0.2† 3.7 ± 0.5 3.0 ± 0.6
 tumors (n) (7) (18) (15) (10) (8)
Subcutaneous bladder 2.1 ± 0.2 1.5 ± 0.2† 1.3 ± 0.1† 1.8 ± 0.2 2.3 ± 0.4
 tumors (n) (8) (20) (17) (12) (5)
*Data presented as mean ± standard deviation; (n) represents animal number; †p < 0.01. BCG = bacille Calmette-Guérin.
and inducing apoptosis and necrosis by acting on different 
types of VEGFs, such as several agents that were demon-
strated to be beneficial against bladder carcinoma. Silay 
et al suggested that these two new agents may also theo-
retically increase the progression-free survival of patients 
with advanced bladder carcinoma because of their an-
tiangiogenic and tumor cell apoptotic effects.18 Bradley 
et al conducted an anti-VEGFR monotherapy phase II 
therapy trial using sunitinib in advanced bladder cancer 
patients after chemotherapy.19 Dreicer et al. reported that 
using sorafenib as a single agent has minimal activity in 
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patients with advanced urothelial cancer in the second-line 
setting.20 Gallagher et al. reported that sunitinib treatment 
did not reach the predetermined therapeutic threshold 
in metastatic urothelial cancer patients, but antitumor 
responses were observed.21
To date, the precise mechanism of action of intra-
vesical BCG remains unknown. Mycobacteria are thought 
to bind to the bladder wall via an interaction between 
the bacterial antigen 85 complex and fibronectin.22,23 
A likely scenario is that exposure to BCG acts as a danger 
signal, which activates local dendritic cells.24 Activated 
dendritic cells may then migrate to local lymph nodes 
where peptides of BCG and TCC origin are presented to 
T lymphocytes. The differentiation of native CD4-positive 
T cells into the T-helper type 1 subset is indispensable 
for successful treatment of superficial bladder cancer 
with BCG.25 The activated T lymphocytes then migrate 
to the urothelium and lyse TCC cells, either directly 
through CD8-positive population or indirectly by activat-
ing natural killer cells. These facts emphasize the impor-
tance of secondary immune reactions in obtaining a 
cytotoxic effect of BCG against TCC tumor cells in addi-
tion to cytokine mediation.
To the best of our knowledge, this is the first study to 
examine the effects of the combined inhibition by BCG 
and sunitinib in bladder cancer cells. The specific hypoth-
esis of this study is that sunitinib in conjunction with 
BCG decreases the recurrence incidence of superficial 
bladder cancer better than standard intravesical chemo-
therapy or immunotherapy with BCG alone. Theoretically, 
this combined regimen should also be beneficial for 
advanced bladder cancer.
In this study, the in vitro effect of combined treat-
ment with BCG and sunitinib was not compatible with 
in vivo animal study results, including tumor growth inhi-
bition and survival time prolongation. A synergistic effect 
of sunitinib on BCG cytotoxicity has not been observed 
in animal models of localized bladder cancer. This indi-
cates that certain antitumor effects of BCG or sunitinib 
alone are specifically mediated and conducted in animal 
hosts, and these do not exist in an in vitro culture envi-
ronment. Hipp et al. reported that sorafenib (Nexavar), 
but not sunitinib, affects the function of dendritic cells and 
induction of primary immune responses.26 The number of 
regulatory T cells is reduced in peripheral blood mono-
nuclear cells in mice treated with sunitinib. Those results 
indicate that sorafenib, but not sunitinib, is theoretically 
more suitable for combination with immunotherapeutic 
approaches to treat cancer patients. In contrast, the 
major cytotoxic effect of BCG on TCC cells is likely to be 
caused by a secondary immune response by activation 
of various killer cells.
The reason that we observed synergistic cytotoxicity 
of BCG and sunitinib in in vitro-cultured TCC cells in this 
study was because of the combined direct cytotoxic ef-
fect of both reagents. Three pathways have been pro-
posed for the direct killing effect of BCG on tumor cells 
as follows: (1) reactive oxygen species production with 
subsequent mitochondrial damage; (2) apoptosis activa-
tion including caspase activation, apoptosis-inducing fac-
tor, and DNA fragmentation; and (3) necrosis-associated 
chemokine expression, such as nuclear factor-κB, box 1, 
AP1 (activator protein 1), IL-6 (Interleukin-6), and c/EBP 
(CCAAT-enhancer-binding proteins).27,28 In our study, the 
decreased synergistic effect of BCG and sunitinib in ortho-
topic bladder and subcutaneous TCC models, with either 
synchronous or metachronous cotreatment, may have 
been due to redistribution or metabolism of sunitinib 
within animals or an inadequate dosage resulting in a 
lower efficacy, although BCG treatment can induce a more-
powerful systemic immune response in the same time 
frame. The underlying causes need to be addressed through 
further research. The underlying mechanism of why met-
achronous sunitinib treatment can antagonize BCG’s 
effect on TCC tumor growth also needs further evaluation. 
This may be caused by cross linkages of sunitinib bystand-
ers after intravesical instillation with BCG subantigens 
resulting in a decreased immune response locally and 
systemically in mice.
Our study findings suggest the possibility and feasi-
bility of immuno-targeted combination therapy for blad-
der cancer in the future. Marked increases in IL-1 and 
IL-2 cytokines were observed in the serum of mice with 
BCG and sunitinib cotreatment. In contrast, general inhi-
bition of measured cytokines, including IL-1, IL-2, VEGF, 
MCP-1, and RANTES, were observed with individual BCG 
and sunitinib treatment. These various manifestations 
may be related to the reagent dose or the limited 
number of cytokines that we measured. The therapeutic 
efficacy may originate from other major cytokines in 
BCG treatment or mediators in sunitinib treatment.
RANTES/CCL5 is a chemokine (CC motif) ligand that 
binds to several chemokine receptors and Duffy antigen 
receptor for chemokines.29 It is expressed by macro-
phages, endothelial cells, keratinocytes, and T cells, and 
plays a key role in inflammation, cell recruitment, and T 
cell activation. It is reasonable to expect that such broad 
expression relies on post-translational proteolytic process-
ing as a means of modulating immunological activity and 
receptor binding. Both MCP-1 and RANTES have also 
been shown to induce the formation of trp RNA-binding 
attenuation protein-positive, multinuclear cells from mac-
rophage colony-stimulating factor-treated monocytes.
Currently, a number of different strategies to inhibit 
VEGF signal transduction are in development, including 
development of humanized neutralizing anti-VEGF mono-
clonal antibodies, receptor antagonists, soluble recep-
tors, antagonistic VEGF mutants, and inhibitors of VEGF 
receptor function. Experimental and clinical data, includ-
ing the approval of the multitargeted drugs sunitinib and 
sorafenib, indicate that exciting results, including tumor 
regression, can be expected from the combined target-
ing of different pathways in the tumor angiogenesis sce-
nario. One strategy is to employ sequential or combination 
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targeted therapy. Another approach is to use other classes 
of targeted therapies either in combination or in sequen-
tial therapy after the development of treatment resistance. 
However, most of these possibilities came from mRCC 
with few examples in bladder cancer, especially for topical 
intravesical therapy of superficial bladder cancer, which 
has relatively low angiogenic activity.
In conclusion, the feasibility of BCG combined with a 
VEGF inhibitor for treating localized bladder cancer did 
not show solid supporting evidence of synergistically de-
creasing the tumor incidence or growth rate from the 
preliminary results of our study.
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